Ipca Laboratories' Q1 FY 2025-26 Quarterly Results

Result Summary

• Ipca Laboratories Ltd reported a 14.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 10.8%.
• Its expenses for the quarter were up by 9.4% QoQ and 10.3% YoY.
• The net profit increased 17410.5% QoQ and increased 16.9% YoY.
• The earnings per share (EPS) of Ipca Laboratories Ltd stood at 9.2 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Ipca Laboratories Ltd is a well-established entity in the pharmaceutical industry, known for its comprehensive range of products that include formulations and active pharmaceutical ingredients (APIs). The company is recognized for its focus on developing and manufacturing a diversified portfolio of products that cater to various therapeutic areas. While specific recent developments within the company are not detailed in the provided data, Ipca Laboratories has historically been involved in both domestic and international markets, supporting its operations through extensive research and development initiatives. The company operates in a highly regulated industry, which includes stringent quality standards and compliance protocols.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Ipca Laboratories Ltd recorded a total income of ₹2341.51 crores. This represents a quarter-over-quarter (QoQ) increase of 14.1% from ₹2051.93 crores in the fourth quarter of fiscal year 2025 (Q4FY25), and a year-over-year (YoY) growth of 10.8% compared to ₹2113.24 crores in the first quarter of fiscal year 2025 (Q1FY25). The consistent increase in revenue over both the quarterly and yearly periods underscores the company's ability to generate higher income from its operations.

Profitability

The profit before tax for Q1FY26 was ₹330.51 crores, showing a substantial QoQ increase of 331.5% from ₹76.60 crores in Q4FY25, and a YoY rise of 13.8% from ₹290.39 crores in Q1FY25. The company's profit after tax was ₹232.89 crores, a dramatic QoQ growth of 17410.5% from ₹1.33 crores in Q4FY25, and a YoY increase of 16.9% from ₹199.14 crores in Q1FY25. The earnings per share (EPS) was ₹9.20, compared to ₹2.40 in Q4FY25 and ₹7.60 in Q1FY25, reflecting a QoQ increase of 283.3% and a YoY growth of 21.1%. These figures highlight the company's enhanced profitability performance during the current quarter.

Operating Metrics

Total expenses for Q1FY26 amounted to ₹2011.00 crores, reflecting a QoQ increase of 9.4% from ₹1838.61 crores in Q4FY25, and a YoY rise of 10.3% from ₹1822.85 crores in Q1FY25. The tax expense for the quarter was ₹96.09 crores, marking a QoQ increase of 30.4% from ₹73.69 crores in Q4FY25 and a YoY increase of 5.1% from ₹91.41 crores in Q1FY25. These metrics indicate the company's operational adjustments and tax obligations relative to its revenue generation and profitability improvements.